The Mr. Green bodega sits on a busy stretch of Bedford Avenue in Brooklyn, New York, offering a retail experience that mirrors the eclectic and often unregulated nature of the modern "biohacking" movement. Situated among the standard convenience store fare—candy bars, chewing gum, rolling papers, and refrigerated sodas—is a shelf containing products far more potent and medically complex: vials of injectable peptides. These substances, once the niche interest of elite athletes and experimental bodybuilders, have migrated from the dark corners of the internet to the glass counters of New York City smoke shops and bodegas. Following a series of viral social media posts highlighting this availability, an investigation was launched to determine the legitimacy and safety of these over-the-counter medical products.
The acquisition process at Mr. Green was notably informal. For a total of $376.20, four distinct varieties of vials produced by a vendor known as INDR Labs were purchased: PT-141, marketed for low libido; BPC-157, touted for muscle recovery and systemic healing; NAD+, sold for cellular repair and anti-aging; and retatrutide, a potent, unapproved experimental weight-loss compound. The transaction concluded with the clerk placing the vials into an unlabeled brown paper bag, a stark contrast to the stringent dispensing protocols required for pharmaceutical-grade injectables. To verify the contents of these vials, they were submitted for rigorous independent testing.
The Laboratory Results: A Study in Pharmaceutical Discrepancy
The samples were sent to Finnrick, an Austin-based startup specializing in independent peptide verification. Finnrick serves as a conduit between individual consumers and specialized laboratories, providing analysis on purity, quantity, and the presence of harmful contaminants. After several weeks of testing, the results provided a bifurcated view of the products’ quality. On one hand, the samples contained negligible levels of heavy metals and endotoxins, suggesting that the manufacturing process—while unregulated—did not introduce immediate toxic pollutants.
However, the primary findings were significant: the vials contained none of the active ingredients listed on their labels. The analysis, referred to as a "label claim analysis," compared the substances within the vials against established chemical standards for BPC-157, PT-141, and the other marketed compounds. In every instance, the samples failed to match the standards. According to Marco Krause, the chief executive officer of the laboratory that performed the tests, the vials were effectively "duds."
The absence of the active compounds suggests two primary possibilities: the vials were intentionally mislabeled by the manufacturer, or the ingredients had undergone extreme degradation. Peptides are notoriously fragile chains of amino acids that are highly sensitive to environmental factors. Most require constant refrigeration and protection from light to maintain their molecular integrity. In a bodega setting, where such products are often stored on standard shelving or behind glass counters without temperature control, the risk of chemical corruption is near-certain.
The Cultural and Political Rise of Peptides
The surge in demand for peptides is not an isolated phenomenon but rather the result of a convergence of celebrity endorsement, "biohacking" culture, and the massive success of GLP-1 agonists like Ozempic and Wegovy. High-profile figures, including podcaster Joe Rogan and U.S. health secretary appointee Robert F. Kennedy Jr., have frequently discussed the benefits of peptides for longevity and physical optimization. This mainstreaming of once-obscure biochemicals has created a multi-billion-dollar "gray market."
While some peptides, such as insulin and certain GLP-1 medications, are FDA-approved and strictly regulated, many of the most popular compounds in the current craze have never completed the clinical trial process required for human consumption. Retatrutide, for instance, is a "triple agonist" currently in Phase 3 clinical trials. It is not yet approved for sale or prescription by any regulatory body, yet it is openly marketed in Brooklyn bodegas as a weight-loss solution.
This ecosystem is currently estimated by investors to be worth upwards of $3 billion. The market thrives on the "Research Use Only" (RUO) loophole. By labeling vials for "research purposes" and "not for human consumption," vendors attempt to circumvent the Federal Food, Drug, and Cosmetic Act. However, when these products are sold in retail environments alongside lifestyle goods and marketed for specific physical ailments, the RUO designation becomes a thin legal fiction that federal agencies are increasingly scrutinizing.
Chronology of a Booming Shadow Market
The timeline of the peptide boom reflects a rapid shift from digital forums to physical retail:
- 2020–2022: The COVID-19 pandemic accelerates interest in self-optimization and "at-home" medical interventions. Online forums like Reddit see a surge in "peptide sourcing" communities.
- Late 2023: The success of tirzepatide and semaglutide creates a massive shortage of weight-loss drugs, driving consumers toward compounded or "research-grade" alternatives.
- Summer 2024: Viral videos on TikTok and Instagram showcase Brooklyn bodegas and smoke shops selling injectable peptides over the counter.
- August 2024: Laboratory results from independent investigations reveal that many of these over-the-counter products are mislabeled or contain no active ingredients.
- September 2024: Increased media scrutiny leads some vendors, such as INDR Labs, to restrict access to their websites and certificates of analysis (COAs).
Verification Failures and Manufacturer Responses
The investigation into INDR Labs revealed further inconsistencies. Prior to the recent scrutiny, the company provided COAs that supposedly verified the purity of their products. These documents claimed the testing had been performed by Vanguard Laboratory. However, when contacted for verification, a spokesperson for Vanguard Laboratory explicitly denied issuing the paperwork, suggesting the certificates were either forged or used without authorization.
When WIRED and other outlets attempted to reach INDR Labs for comment, the company’s digital footprint shifted. Its website, which previously allowed public access to product listings and "verification" documents, was placed behind a login wall. This pattern of behavior is common in the "turnkey" peptide industry, where small brands use the same upstream suppliers—often located in China—to bottle and label products with little to no oversight of the final contents.
Raphaël Mazoyer, CEO of Finnrick, noted that his company has seen a significant uptick in "dud" results over the past quarter. He attributes this to the proliferation of low-barrier-to-entry businesses that prioritize marketing over batch testing. "There are a whole bunch of labels popping up that have the same upstream vendor," Mazoyer stated, highlighting a systemic lack of accountability in the supply chain.
Regulatory Stance and Public Safety Implications
The FDA has expressed growing concern over the sale of unapproved peptides. An agency spokesperson stated that the FDA has issued multiple warning letters to companies marketing RUO products directly to consumers for human use. Furthermore, the agency has targeted telehealth platforms that make misleading claims regarding compounded GLP-1 products.
The safety risks of this unregulated trade are not merely theoretical. While the "duds" found at Mr. Green may only result in financial loss for the consumer, other mislabeled products have had fatal consequences. Earlier this year, a woman in the Bronx died after receiving a peptide injection at an unlicensed medical spa. In another case, a seller in Indiana was sentenced to six years in prison for distributing "research" peptides that were found to be adulterated with anabolic steroids.
Darshan Kulkarni, an attorney specializing in pharmaceutical regulatory compliance, argues that the current environment is "legitimizing products without any understanding of their safety or accuracy profile." He notes that traditional pharmaceutical distribution relies on a chain of custody—including visual inspections, temperature-controlled logistics, and barcoding—that is entirely absent in the bodega setting.
Analysis of the "Right to Try" vs. Consumer Protection
The persistence of these products in New York shops highlights a philosophical and regulatory divide. Some legal experts, including Kulkarni, suggest that the lack of aggressive enforcement may be a lingering effect of a deregulatory political climate that emphasizes "patient autonomy" and the "Right to Try" over centralized FDA control. Proponents of this view argue that individuals should have the right to experiment with their own biochemistry without government interference.
However, the "bodega peptide" phenomenon challenges this libertarian ideal by introducing a high probability of fraud. When a consumer buys a vial labeled "Retatrutide" and receives nothing but saline solution, the issue is no longer about the right to experiment—it is about consumer fraud and public health endangerment. As the peptide industry continues its trajectory toward a $3 billion valuation, the pressure on federal and local authorities to close the RUO loophole and conduct "boots-on-the-ground" enforcement at retail locations is likely to intensify.
As of early September, despite the removal of large window advertisements at Mr. Green, the peptides remained available for purchase. The menu had merely been moved to a less conspicuous location near the counter, illustrating the resilience of a market that operates in the shadows of the law but in plain sight of the public.
About the Author
